Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead
Arcus Biosciences’ casdatifan combinations produced competitive early renal-cell carcinoma results, but PEAK-1 and PEAK-20 Phase 3 trials…
Petri Dish Reports NYSE
Arcus Biosciences, Inc.
RCUS
1 story
$2.8B Market cap · 2026-10-20
Petri Dish Reports 